HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Synthesis of 1,2-benzisoxazole tethered 1,2,3-triazoles that exhibit anticancer activity in acute myeloid leukemia cell lines by inhibiting histone deacetylases, and inducing p21 and tubulin acetylation.

Abstract
1,2,3-Triazole-based heterocycles have previously been shown to possess significant anticancer activity in various tumor models. In the present study, we attached a 1,2,3-triazole moiety to the third position of a 1,2-benzisoxazole heterocycle via copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC) with various alkynes and established for the title compounds significant antiproliferative effect against human acute myeloid leukemia (AML) cells. Among the tested compounds, 3-(4-(4-phenoxyphenyl)-1H-1,2,3-triazol-1-yl)benzo[d]isoxazole (PTB) was found to be the most potent antiproliferative agent with an IC50 of 2 μM against MV4-11 cells using MTT assay. Notably, PTB induced cytotoxicity in MOLM13, MOLM14 and MV4-11 cells with selectivity over normal bone marrow cells (C57BL/6). Furthermore, PTB was found to induce cytotoxicity by increasing apoptosis of AML cells (MOLM13, MOLM14 and MV4-11) as well as sub-G1 cell population and apoptotic cells at submicromolar concentrations, as shown by flow cytometry and Annexin-V staining, respectively. On the protein level we suggested histone deacetylases (HDACs) as the potential protein target of those compounds in silico, and the predicted target was next experimentally validated by measuring the variations in the levels of p21, cyclin D and acetylation of histone H3 and tubulin. Molecular docking analysis of the title compounds with the second deacetylase domain of HDAC6 displayed high degree of shape complementarity to the binding site of the enzyme, forming multiple molecular interactions in the hydrophobic region as well as a hydrogen bond to the phenol side-chain of Tyr-782. Thus, 1,2,3-triazole derivatives appear to represent a class of novel, biologically active ligands against histone deacetylases which deserve to be further evaluated in their applications in the cancer field.
AuthorsNanjundaswamy Ashwini, Manoj Garg, Chakrabhavi Dhananjaya Mohan, Julian E Fuchs, Shobith Rangappa, Sebastian Anusha, Toreshettahally Ramesh Swaroop, Kodagahalli S Rakesh, Deepika Kanojia, Vikas Madan, Andreas Bender, H Phillip Koeffler, Basappa, Kanchugarakoppal S Rangappa
JournalBioorganic & medicinal chemistry (Bioorg Med Chem) Vol. 23 Issue 18 Pg. 6157-65 (Sep 15 2015) ISSN: 1464-3391 [Electronic] England
PMID26299825 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2015 Elsevier Ltd. All rights reserved.
Chemical References
  • 1,2-benzisoxazole
  • Antineoplastic Agents
  • Cyclin D
  • Cyclin-Dependent Kinase Inhibitor p21
  • Histone Deacetylase Inhibitors
  • Histones
  • Isoxazoles
  • Triazoles
  • Tubulin
  • Histone Deacetylases
Topics
  • Acetylation
  • Animals
  • Antineoplastic Agents (chemical synthesis, chemistry, toxicity)
  • Apoptosis (drug effects)
  • Cell Line, Tumor
  • Cell Proliferation (drug effects)
  • Cyclin D (metabolism)
  • Cyclin-Dependent Kinase Inhibitor p21 (metabolism)
  • G1 Phase Cell Cycle Checkpoints (drug effects)
  • Histone Deacetylase Inhibitors (chemical synthesis, chemistry, toxicity)
  • Histone Deacetylases (chemistry, metabolism)
  • Histones (metabolism)
  • Humans
  • Isoxazoles (chemistry)
  • Leukemia, Myeloid, Acute (metabolism, pathology)
  • Mice
  • Mice, Inbred C57BL
  • Triazoles (chemical synthesis, chemistry, toxicity)
  • Tubulin (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: